ALS Phase 3 Study Dexpramipexole (KNS-760704)

What is ALS Phase 3 Study Dexpramipexole (KNS-760704)?

CATEGORY:

NCT01281189 is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Dexpramipexole was previously known as KNS-760704. Other study IDs: EMPOWER, 223AS302, EUDRA CT NO:2010-022818-19.

Save up to 80% off your prescriptions!

How do members experience ALS Phase 3 Study Dexpramipexole (KNS-760704)?

Top 5 reported purposes & perceived effectiveness

Purpose Patients Evaluations Perceived Effectiveness
Amyotrophic lateral sclerosis 37 95
Participate in clinical trial 17 21
Increase effect of another treatment 2 14
Arthritis pain in shoulder joints 1 0

Common side effects

Side effect Patients Percentage
Nausea 3
Heartburn 2
Insomnia 2
Neutropenia (low neutrophils) 2
Oily facial skin 2
Burning sensation in eyes 1

Side effect severity

Side effects as an overall problem
Severity Evaluations Percentage
Severe 4
Moderate 4
Mild 28
None 65

Member evaluations

AustinMJ

evaluated on Jan 16, 2013

  • Perceived effectiveness for amyotrophic lateral sclerosis: Can't tell
  • Side effects: None
r

Root10996

evaluated on Oct 10, 2012

  • Perceived effectiveness for Participate in clinical trial: Can't tell
  • Side effects: None

fki2001

evaluated on Oct 11, 2012

  • Perceived effectiveness for Participate in clinical trial: Can't tell
  • Side effects: None
Learn more about our community’s experience with ALS Phase 3 Study Dexpramipexole (KNS-760704)

What are people saying about ALS Phase 3 Study Dexpramipexole (KNS-760704)?

70

70

members have reported taking ALS Phase 3 Study Dexpramipexole (KNS-760704)

Join the conversation and connect with people who have taken ALS Phase 3 Study Dexpramipexole (KNS-760704)
Last updated:

Save up to 80% off your prescriptions!

ADVERTISEMENT

ADVERTISEMENT